In The News

    • AUG 24 2015

    Oncoceutics Selected as Finalist for “The Buzz of BIO”

    The biotechnology trade group BIO has selected Oncoceutics as one of 10 finalists in a competition called “The Buzz of BIO”. Winners will be featured at the BIO Investor Forum that attracts leading pharmaceutical companies interested in the cutting edge of biotechnology. Vote here: https://www.bio.org/node/98373?utm_source=Highroads&utm_medium=email&utm_campaign=2015-08-24-BIF-2015-BuzzVoting&utm_term=Vote-Now-BTN

    • JUL 06 2015

    Pediatric Patients Could Benefit Most From New Oncoceutics Cancer Drug. | BioSpace Exclusive

    BioSpace reports that small molecule ONC201 being developed by Oncoceutics is particularly promising for the treatment of pediatric patients, and may be an option when other therapies are no longer effective. http://www.biospace.com/News/exclusive-pediatric-patients-could-benefit-most/383472